Company intelligence / Profile preview

Mannin Research Inc.

Toronto, Ontario, Canadamannin.ca ↗
Ownership
Private
Development stage
Other
01

Overview

Mannin Research Inc. develops novel therapeutics targeting vascular diseases using proprietary platforms focused on the Tie2 receptor and angiopoietin pathways. Lead preclinical data show promise in glaucoma, acute kidney injury, and infectious disease models. The company has received significant grant funding to advance its pipeline.

Therapeutic areas
OphthalmologyCardiovascularInfectious DiseasesNephrology
Modalities
Small moleculesFusion proteins
Industry
Biotech
02

Drug pipeline

4 assets

Ang1-C4bp

Preclinical

3 more assets in the full pipeline.

03

Partnerships

Cyclica Inc. – joint venture for rapid development of COVID‑19 drugs using AI-driven drug discovery and Tie2 expertise

Beyond the preview

Go deeper on Mannin Research Inc..

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

  • Partners
  • Deal terms
  • Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

  • Funding rounds
  • Investors
  • Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

  • Peer companies
  • Targets
  • Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

  • Platforms
  • Patents
  • Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

  • Company news
  • Sources
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Mannin Research Inc..

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call